Thyrotropin alfa
FDA approved · RxRecombinant thyroid-stimulating hormone
Also known as: Thyrogen, TSH
Strong, human-grade evidence
- Regulatory standing. FDA-approved prescription medicine
- Human trials. Backed by controlled human studies
- Registered human trials. 108 registered studies on ClinicalTrials.gov, most advanced Phase 4
- 1 cited source. Includes primary / regulatory sources
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Thyrotropin alfa is a lab-made (recombinant) version of human thyroid-stimulating hormone, sold under the brand name Thyrogen. It binds TSH receptors on thyroid cells, including remaining thyroid tissue or thyroid cancer cells, and stimulates them to take up radioactive iodine and release thyroglobulin. This allows testing and treatment without stopping thyroid hormone replacement.
What the evidence shows
It is FDA approved for use as a diagnostic aid in thyroglobulin testing and radioiodine imaging in people with well-differentiated thyroid cancer, and approved for use alongside radioiodine to ablate remaining thyroid tissue after thyroidectomy. Its role is supported by over 100 registered human trials reaching Phase 4, while uses outside these indications are less established.
Key facts
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
Dual Trigger" in IVF Patients at High Risk of Ovarian Hyper Stimulation Syndrome
Low-dose Gonal-f® in Ovulation Induction
A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours
Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.
Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain.
High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal.
Sources
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.